Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Cash & Equivalents (2022 - 2025)

Oramed Pharmaceuticals' Cash & Equivalents history spans 4 years, with the latest figure at $45.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents changed N/A year-over-year to $45.9 million; the TTM value through Dec 2025 reached $45.9 million, changed N/A, while the annual FY2025 figure was $45.9 million, N/A changed from the prior year.
  • Cash & Equivalents reached $45.9 million in Q4 2025 per ORMP's latest filing, up from $868000.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $84.8 million in Q2 2024 to a low of $435000.0 in Q2 2025.
  • Average Cash & Equivalents over 4 years is $29.6 million, with a median of $28.0 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 1152.45% in 2024, then plummeted 99.49% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $40.5 million in 2022, then plummeted by 77.62% to $9.1 million in 2023, then skyrocketed by 364.98% to $42.1 million in 2024, then grew by 9.13% to $45.9 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Cash & Equivalents are $45.9 million (Q4 2025), $868000.0 (Q3 2025), and $435000.0 (Q2 2025).